Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity. billion, Mirati for $5.8

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Cooley M&A

FEBRUARY 1, 2024

2023’s much-discussed downturn in mergers & acquisitions – with global M&A volume and value down 6% and 17%, respectively, from 2022 – was largely driven by the slowdown in the tech sector, with global tech M&A volumes down 51% year over year, while other sectors saw marked increases. [1] in 2022 to 5.9x

M&A 59

M&A Mergers and Acquisitions Private Equity Equities 59

Mergers and Inquisitions

NOVEMBER 1, 2023

This chart of PE deal activity from 2001 to 2022 in the Bain Capital Healthcare Private Equity report sums up the market quite well: In short, healthcare had never been a huge sector for private equity, but activity ramped up in the late 2010s into the early 2020s, and it’s now one of the top industries by dollar volume (right after tech).

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Cooley M&A

APRIL 13, 2022

We have reviewed the bylaws of a number of corporations that have gone public through a deSPAC or traditional IPO process. We suggest that companies going public through a traditional IPO or deSPAC transaction draft the advance notice bylaws to account for the first annual meeting. 14, 2022), at 38. Inter-Tel (Del.

Corporation 52

Corporation IPO Mergers IT 52

Razorpay

JUNE 8, 2023

Apart from being a safe place to keep money, banks also provide savings accounts that give the account owner interest on their deposit so that the money is not sitting idle. Businesses store money in checking accounts or current accounts. These are special accounts designed for the financial needs of a business.

Banking 52

Banking Bank Accountant Financial Institution 52

Cooley M&A

SEPTEMBER 16, 2022

There are compelling rationales for adopting a dual-class structure, but even proponents of the structure generally acknowledge that these benefits are significantly mitigated once the dual-class shares are out of the hands of the founders and/or pre-IPO stockholders. Potential carve outs for M&A voting agreements. Stockholder litigation.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

OfficeHours

AUGUST 20, 2023

Once improved, the exit can then take place, usually in the form of another sale or an Initial Public Offering (IPO), both of which are usually under the advice of an investment bank. Visit the OfficeHours Blog and follow us on our social media accounts: Instagram , LinkedIn , YouTube , TikTok , and Twitter for our latest updates.+

Private Equity 130

Private Equity Equities Investment Banking Finance 130

The TRADE

MAY 30, 2024

Engaged by the buy- and sell-side in 2022 to explore the functional use cases of a consolidated tape, the firm is now exploring becoming an industry led candidate to rival EuroCTP. “We There is established EU guidance on bidding consortia and that is something we’d have to take into account,” adds Tiefenbrun.

Equities 52

Equities Consulting Trading IT 52

Cooley M&A

JANUARY 10, 2022

As SPAC IPOs broke records – in both value and volume – in 2020 (and again in 2021), it was inevitable that stockholder litigation would follow. January 3, 2022), the Court of Chancery had the first opportunity, in connection with a motion to dismiss hearing, to consider application of Delaware law in the context of a deSPAC transaction.

Shares 40

Shares IPO Mergers IT 40

Cooley M&A

JANUARY 20, 2022

While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. on transactions dominating the life sciences landscape into 2022. [4].

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40